BEDFORD, Ohio, Jan. 14 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., is pleased to announce FDA approval for the addition of 100 mg/50 mL Fluconazole Injection to its existing Fluconazole Injection line. This product is AP rated and is equivalent to Diflucan(R) by Pfizer. Fluconazole Injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated for the prophylaxis of candidiasis.
“Pharmacists asked, we answered. In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to be the first to offer this unique dosage. Fluconazole Injection 100 mg/50 mL is right-sized for smaller doses, speeding productivity and saving time. This continues to demonstrate our commitment to providing a broad-based portfolio of products,” said David Gaugh, Vice President of Bedford Laboratories.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.
About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people. For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
Diflucan(R) is a registered trademark of Pfizer Inc.
CONTACT: Jason Kurtz, Editorial Contact, Bedford Laboratories,
+1-440-201-3668, jason.kurtz@boehringer-ingelheim.com
Web site: http://www.bedfordlabs.com/
